trial

Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients

NCTId NCT00882518
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 388 (actual)
Sponsored by AstraZeneca
Primary completion 2010-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
388 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2009-04
Primary completion
2010-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
QuetiapineChlorpromazine

Sponsors

AstraZenecaLead Sponsor

Investigators

2
Niufan Gu, MDPrincipal Investigator
Michael CastiglioneStudy Director

Sites

11 total
Hunan, ChinaGuangzhou, ChinaBaoding, ChinaHarbin, ChinaWuhan, ChinaChangsha, ChinaNanjing, ChinaXi’an, ChinaKunming, ChinaBeijing, ChinaShanghai, China

Linked catalysts

1
Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Pat — primary completion2010-07

Facts & assertions

4 sourced
Enrollment
388
Phase
PHASE3
Primary Completion Date
2010-07
Status
COMPLETED
relationships
The graph out of here
drug
Quetiapine
drug
Chlorpromazine
drug
lead_sponsor
AstraZeneca
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Niufan Gu, MD
person
Michael Castiglione
person